Energy Co. Initiates Strategic Process to Spin-off Hydrogen Portfolio
Source: Nicholas Cortellucci 04/18/2024
In light of Jericho Energy Ventures Inc.’s recent news, Atrium Research analysts reiterated their Buy rating and CA$0.50 target price.
Yesterday, after the market close, Jericho Energy Ventures Inc. (JEV:TSX.V; JROOF:OTC; JLM:FRA) announced that it has commenced a strategic process to explore the spin-off and separate listing of its hydrogen platform. This was reported on by Atrium Research analysts Nicholas Cortellucci and Ben Pirie in an April 18 research note.
“We view a potential spin-off as a great outcome for shareholders as the value of both JEV’s O&G [oil and gas] and hydrogen assets will be better appreciated in their own separate entities,” the analysts commented.
The proposed spin-off has the goal of producing two independent, streamlined, pure-play companies focused on becoming leaders in their respective markets, oil and gas production in Oklahoma, and hydrogen energy technologies.
“Each business will have an appropriate capital structure and management team to support creating maximum shareholder value,” the company stated. If successful, the oil and gas business will remain with Jericho Energy Ventures, while the hydrogen assets will be moved to a new entity.
As for the O&G entity, the analysts believe “the proposed transaction will provide much greater visibility as the economics of its assets were previously hidden by JV accounting. We think this will allow investors to better appreciate the assets which were last reported to have a PV-10 (proven reserves only) of US$44M or CA$0.29/share.”
On the hydrogen front, “the proposed transaction will allow the new entity to attract energy transition and ESG investors, which previously shied away due to the hydrocarbon aspect,” noted the analysts. Just a reminder, JEV’s hydrogen projects were doing really well towards the end of 2023. They got funding from the U.S. Department of Energy, made a deal with Superior Boiler to manufacture something, had good test results from H2U, partnered with Exogen & Lhyfe SA, and even got their first order for a boiler
To support the proposed transaction, Jericho recently closed a US$2.2M private placement and amended terms on its debentures. “On March 6, JEV announced that it closed a US$2.2M non-brokered private placement of 11.1M units at US$0.20/unit, including one warrant at US$0.24/share. The financing was led by insiders and existing shareholders,” the analysts highlighted. “Additionally, on April 5, Jericho announced that it amended the conversion price on its debentures and extended their maturity along with the associated warrants.”
In other recent news, JEV’s portfolio company, H2U Technologies, entered into a research and development agreement in December with De Nora, the world’s largest supplier of high-performing catalyst-coated membranes.
“The agreement aims to identify and develop low-cost, high-performance electrocatalysts for hydrogen production through water electrolysis. These catalysts are expected to enable the market presence of affordable green hydrogen,” explained the analysts
Atrium Research continues to value JEV using a sum-of-the-parts methodology, including the O&G assets at CA$0.19/share (0.7x NPV), Hydrogen Technologies at CA$0.25/share (4.5x 2025E sales), and its minority hydrogen investments at CA$0.03/share (cost). The firm reiterated its Buy rating and CA$0.50 per share target price, representing a potential return of 163% from current levels.
Sign up for our FREE newsletter at: www.streetwisereports.com/get-news
Important Disclosures:
- Jericho Energy Ventures Inc. is a billboard sponsor of Streetwise Reports and pays SWR a monthly sponsorship fee between US$4,000 and US$5,000. In addition, Jericho Energy Ventures Inc. has a consulting relationship with an affiliate of Streetwise Reports, and pays a monthly consulting fee between US$8,000 and US$20,000.
- As of the date of this article, officers and/or employees of Streetwise R
- This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports’ terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
For additional disclosures, please click here.
Disclosures for Atrium Research, Jericho Energy Ventures Inc., April 18, 2024
Analyst Certification Each authoring analyst of Atrium Research on this report certifies that (i) the recommendations and opinions expressed in this research accurately reflect the authoring analyst’s personal, independent and objective views about any and all of the designated securities discussed (ii) no part of the authoring analyst’s compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in the research, (iii) to the best of the authoring analyst’s knowledge, she/he is not in receipt of material non-public information about the issuer, (iv) the analyst does not own common shares, options, or warrants in the company under coverage, and (v) the analysts adhere to the CFA Institute guidelines for analyst independence.
About Atrium Research Atrium Research provides institutional quality issuer paid research on public equities in North America. Our investment philosophy takes a 3-5 year view on equities currently being overlooked by the market. Our research process emphasizes understanding the key performance metrics for each specific company, trustworthy management teams, unit economics, and an in-depth valuation analysis. For further information on our team, please visit https://www.atriumresearch.ca/team.
General Information Atrium Research Corporation (ARC) has created and distributed this report. This report is based on information we considered reliable; we have not been provided with any material non-public information by the company (or companies) discussed in this report. We do not represent that this report is accurate or complete and it should not be relied upon as such; further any information in this report is subject to change without any formal or type of notice provided. Investors should consider this report as only one factor in their investment decisions; this report is not intended as a replacement for investor’s independent judgment. ARC is not an IIROC registered dealer and does not offer investment-banking services to its clients. ARC (and its employees) do not own, trade or have a beneficial interest in the securities of the companies we provide research services for and does not serve as an officer or Director of the companies discussed in this report. ARC does not make a market in any securities.
This report is not disseminated in connection with any distribution of securities and is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. ARC does not make any warranties, expressed or implied, as to the results to be obtained from using this information and makes no express of implied warranties for particular use. Anyone using this report assumes full responsibility for whatever results they obtain. This does not constitute a personal recommendation or take into account any financial or investment objectives, financial situations or needs of individuals.
This report has not been prepared for any particular individual or institution. Recipients should consider whether any information in this report is suitable for their particular circumstances and should seek professional advice. Past performance is not a guide for future results, future returns are not guaranteed, and loss of original capital may occur. Neither ARC nor any person employed by ARC accepts any liability whatsoever for any direct or indirect loss resulting from any use of its research or the information it contains. This report contains “forward looking” statements.
Forward-looking statements regarding the Company and/or stock’s performance inherently involve risks and uncertainties that could cause actual results to differ from such forward-looking statements. Such statements involve a number of risks and uncertainties such as competition, technology shifts, market demand and the company’s (and management’s) ability to correctly forecast financial estimates; please see the company’s MD&A “Risk Factors” Section for a more complete discussion of company specific risks for the company discussed in this report.
ARC is receiving a cash compensation from Jericho Energy Ventures Inc. for 12-months of research coverage. ARC retains full editorial control over its research content. ARC does not have investment banking relationships and does not expect to receive any investment banking driven income. ARC reports are primarily disseminated electronically and, in some cases, printed form. Electronic reports are simultaneously available to all recipients in any form.
Reprints of ARC reports are prohibited without permission. To receive future reports on covered companies please visit https://www.atriumresearch.ca/research or subscribe on our website. The information contained in this report is intended to be viewed only in jurisdictions where it may be legally viewed and is not intended for use by any person or entity in any jurisdiction where such use would be contrary to local regulations or which would require any registration requirement within such jurisdiction.
( Companies Mentioned: JEV:TSX.V; JROOF:OTC; JLM:FRA, )
Source: https://www.streetwisereports.com/article/2024/04/18/energy-co-initiates-strategic-process-to-spin-off-hydrogen-portfolio.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world. Anyone can join. Anyone can contribute. Anyone can become informed about their world. "United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
LION'S MANE PRODUCT
Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules
Mushrooms are having a moment. One fabulous fungus in particular, lion’s mane, may help improve memory, depression and anxiety symptoms. They are also an excellent source of nutrients that show promise as a therapy for dementia, and other neurodegenerative diseases. If you’re living with anxiety or depression, you may be curious about all the therapy options out there — including the natural ones.Our Lion’s Mane WHOLE MIND Nootropic Blend has been formulated to utilize the potency of Lion’s mane but also include the benefits of four other Highly Beneficial Mushrooms. Synergistically, they work together to Build your health through improving cognitive function and immunity regardless of your age. Our Nootropic not only improves your Cognitive Function and Activates your Immune System, but it benefits growth of Essential Gut Flora, further enhancing your Vitality.
Our Formula includes: Lion’s Mane Mushrooms which Increase Brain Power through nerve growth, lessen anxiety, reduce depression, and improve concentration. Its an excellent adaptogen, promotes sleep and improves immunity. Shiitake Mushrooms which Fight cancer cells and infectious disease, boost the immune system, promotes brain function, and serves as a source of B vitamins. Maitake Mushrooms which regulate blood sugar levels of diabetics, reduce hypertension and boosts the immune system. Reishi Mushrooms which Fight inflammation, liver disease, fatigue, tumor growth and cancer. They Improve skin disorders and soothes digestive problems, stomach ulcers and leaky gut syndrome. Chaga Mushrooms which have anti-aging effects, boost immune function, improve stamina and athletic performance, even act as a natural aphrodisiac, fighting diabetes and improving liver function. Try Our Lion’s Mane WHOLE MIND Nootropic Blend 60 Capsules Today. Be 100% Satisfied or Receive a Full Money Back Guarantee. Order Yours Today by Following This Link.